TGFB1 and neoplasm: This study unravels the potential of syndecan‐2‐peptide as an antitumourigenic agent, exerting a novel multi‐modal attenuation of TGFβ signalling, limiting metastasis and reducing tumour growth by relieving immunosuppression mediated by TASCs within the TME.